ONCT (Oncternal Therapeutics) Margin of Safety % (DCF FCF Based) : N/A (As of Apr. 01, 2025)

View and export this data going back to 2004. Start your Free Trial

What is Oncternal Therapeutics Margin of Safety % (DCF FCF Based)?

Margin of Safety % (DCF FCF Based) = (Intrinsic Value: DCF (FCF Based) - Current Price) / Intrinsic Value: DCF (FCF Based).

Note: Discounted FCF model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Oncternal Therapeutics's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF FCF Based) is not calculated.

Competitive Comparison of Oncternal Therapeutics's Margin of Safety % (DCF FCF Based)

For the Biotechnology subindustry, Oncternal Therapeutics's Margin of Safety % (DCF FCF Based), along with its competitors' market caps and Margin of Safety % (DCF FCF Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Oncternal Therapeutics's Margin of Safety % (DCF FCF Based) Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Oncternal Therapeutics's Margin of Safety % (DCF FCF Based) distribution charts can be found below:

* The bar in red indicates where Oncternal Therapeutics's Margin of Safety % (DCF FCF Based) falls into.

Save Embed

;

Save Embed

;

Oncternal Therapeutics Margin of Safety % (DCF FCF Based) Related Terms

Thank you for viewing the detailed overview of Oncternal Therapeutics's Margin of Safety % (DCF FCF Based) provided by GuruFocus.com. Please click on the following links to see related term pages.

Oncternal Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oncternal Therapeutics Inc (NAS:ONCT) » Definitions » Margin of Safety % (DCF FCF Based)

Comparable Companies

Traded in Other Exchanges

N/A

Address

12230 El Camino Real, Suite 230, San Diego, CA, USA, 92130

Website

https://www.oncternal.com

Oncternal Therapeutics Inc is a clinical-stage oncology company developing first-in-class, novel therapies that target a broad spectrum of cancers with a large unmet medical need. The Company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to ROR1 (Receptor-tyrosine kinase-like Orphan Receptor 1), and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoprotein. The Company is also developing ONCT-808, a CAR-T (chimeric antigen receptor T-cells) product candidate that target ROR1, and ONCT-534, a dual-action androgen receptor inhibitor product candidate for the treatment of castration-resistant prostate and other androgen receptor-driven cancers. The Company has one operating segment in the United States.

Executives

Robert James Wills	director, officer: Executive Chairman	175 TOYOTA PLAZA, 7TH FLOOR, MEMPHIS TN 38103
David F Hale	director	1042-B NORTH EL CAMINO REAL, SUITE 430, ENCINITAS CA 92024
Gunnar F. Kaufmann	officer: Chief Scientific Officer	C/O ONCTERNAL THERAPEUTICS, INC., 12230 EL CAMINO REAL, SUITE 300, SAN DIEGO CA 92130
Salim Yazji	officer: Chief Medical Officer	12230 EL CAMINO REAL, SUITE 300, SAN DIEGO CA 92130
James B Breitmeyer	director, officer: President, CEO
Richard G Vincent	officer: Chief Financial Officer	C/O WOMEN FIRST HEALTH CARE, 5355 MIRA SORRENTO PLACE STE. 700, SAN DIEGO CA 92121-3825
Chase C. Leavitt	officer: General Counsel/Secretary	1010 ATLANTIC AVENUE, SUITE 102, ALAMEDA CA 94501
Jill Desimone	director	C/O PRAXIS PRECISION MEDICINES, INC., 99 HIGH STREET, 30TH FLOOR, BOSTON MA 02110
Rajesh Krishnan	officer: Chief Technology Officer	12230 EL CAMINO, SUITE 300, SAN DIEGO CA 92130
Jinzhu Phd Chen	director	12230 EL CAMINO REAL, SUITE 300, SAN DIEGO CA 92130
Michael G Carter	director	C/O CANCER VAX CORP, 2110 RUTHERFORD ROAD, CARLSBAD CA 92008
Daniel L Kisner	director	2292 FARADAY AVENUE, CARLSBAD CA 92008
Hazel M Aker	officer: General Counsel	C/O CANCER VAX CORP, 2110 RUTHERFORD ROAD, CARLSBAD CA 92008
Shanghai Pharmaceutical (usa) Inc.	10 percent owner	C/O ONCTERNAL THERAPEUTICS, INC., 3525 DEL MAR HEIGHTS ROAD #821, SAN DIEGO CA 92130-2122
Shanghai Pharmaceuticals (hk) Investment Ltd	10 percent owner	C/O ONCTERNAL THERAPEUTICS, INC., 12230 EL CAMINO REAL, SUITE 300, SAN DIEGO CA 92130